A review of randomized studies suggests that mineralocorticoid receptor antagonists further reduce proteinuria in patients with diabetes mellitus or non-diabetes mellitus causes of CKD when combined with renin-angiotensin system blockers (37). The gene discussed is NR3C2; the disease is diabetes mellitus.